Literature DB >> 16896646

Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

Luminita Ene1, Tessa Goetghebuer, Marc Hainaut, Alexandra Peltier, Véronique Toppet, Jack Levy.   

Abstract

OBJECTIVE: The aim of this study was to assess the changes in body fat distribution and lipid abnormalities in a population of HIV-infected children and adolescents followed in one single centre who had been exposed, or not, to antiretroviral therapy (ART).
MATERIALS AND METHODS: Patients aged between 3 and 19 years were evaluated in a cross-sectional study carried out between October and December 2002. Fat redistribution was evaluated independently by the physician and the patient. Fasting blood lipid profile, glucose, insulin and C peptide were measured. Among the 88 patients evaluated, 74 were taking ART.
RESULTS: Fat redistribution was present in 20 patients, metabolic alterations alone were found in 22 children and 46 children had neither physical nor metabolic abnormalities. Patients with fat redistribution were found to have been on ART for a significantly longer period of time, with 42% of the children showing fat redistribution having been treated with antiretroviral agents for more than 5 years. These children had also been exposed to a higher number of antiretroviral agents. In contrast, metabolic alterations in the absence of fat redistribution were not related to the duration of ART nor to the number of drugs received. Treatment with stavudine or protease inhibitors was significantly associated with the presence of physical changes.
CONCLUSION: Regular assessment of fat redistribution and metabolic markers should be carried out in children treated with antiretroviral agents and taken into account when adapting therapy during the long-term follow up of these children.

Entities:  

Mesh:

Year:  2006        PMID: 16896646     DOI: 10.1007/s00431-006-0193-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  39 in total

1.  Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.

Authors:  Alessandra Viganò; Stefano Mora; Corrado Testolin; Sabrina Beccio; Laura Schneider; Dorella Bricalli; Angelo Vanzulli; Paola Manzoni; Paolo Brambilla
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-15       Impact factor: 3.731

2.  Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.

Authors:  Véronique Joly; Philippe Flandre; Vincent Meiffredy; Nicolas Leturque; Marine Harel; Jean-Pierre Aboulker; Patrick Yeni
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

3.  An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.

Authors:  A Carr; S Emery; M Law; R Puls; J D Lundgren; W G Powderly
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

4.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; F Bruno; O Rouviere; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

5.  Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.

Authors:  S M Arpadi; P A Cuff; M Horlick; J Wang; D P Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2001-05-01       Impact factor: 3.731

6.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

Authors:  A Carr; J Miller; M Law; D A Cooper
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

7.  Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.

Authors:  D Jaquet; M Lévine; E Ortega-Rodriguez; A Faye; M Polak; E Vilmer; C Lévy-Marchal
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

8.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

9.  Visceral abdominal-fat accumulation associated with use of indinavir.

Authors:  K D Miller; E Jones; J A Yanovski; R Shankar; I Feuerstein; J Falloon
Journal:  Lancet       Date:  1998-03-21       Impact factor: 79.321

10.  Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

Authors:  D Worm; O Kirk; O Andersen; J Vinten; J Gerstoft; T L Katzenstein; H Nielsen; C Pedersen
Journal:  HIV Med       Date:  2002-10       Impact factor: 3.180

View more
  24 in total

1.  High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy.

Authors:  Steve Innes; Kameelah L Abdullah; Richard Haubrich; Mark F Cotton; Sara H Browne
Journal:  Pediatr Infect Dis J       Date:  2016-01       Impact factor: 2.129

Review 2.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

3.  LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.

Authors:  Steve Innes; Leon Levin; Mark Cotton
Journal:  South Afr J HIV Med       Date:  2009-12       Impact factor: 2.744

4.  Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters.

Authors:  Claude Ann Mellins; Elizabeth Brackis-Cott; Cheng-Shiun Leu; Katherine S Elkington; Curtis Dolezal; Andrew Wiznia; Mary McKay; Mahrukh Bamji; Elaine J Abrams
Journal:  J Child Psychol Psychiatry       Date:  2009-02-27       Impact factor: 8.982

5.  Lipodystrophy and metabolic complications of highly active antiretroviral therapy.

Authors:  Ankit Parakh; Anand Prakash Dubey; Ajay Kumar; Anshu Maheshwari
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

6.  Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

Authors:  Grace M Aldrovandi; Jane C Lindsey; Denise L Jacobson; Amanda Zadzilka; Elizabeth Sheeran; Jack Moye; Peggy Borum; William A Meyer; Dana S Hardin; Kathleen Mulligan
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

Review 7.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

8.  Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.

Authors:  Anirban Mandal; Aparna Mukherjee; R Lakshmy; Sushil K Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2015-09-03       Impact factor: 1.967

Review 9.  Pediatric adherence to HIV antiretroviral therapy.

Authors:  Jessica Haberer; Claude Mellins
Journal:  Curr HIV/AIDS Rep       Date:  2009-11       Impact factor: 5.071

10.  A.S.P.E.N. clinical guidelines: nutrition support of children with human immunodeficiency virus infection.

Authors:  Nasim Sabery; Christopher Duggan
Journal:  JPEN J Parenter Enteral Nutr       Date:  2009 Nov-Dec       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.